Canada Spends Logo

Explore our Budget 2026 analysis

Grant: CIHR Fellowship

Université de Montréal

$135,000.00

Innovative characterization of structural variants and differential splicing from RNA-sequencing data of 452 primary human AML specimens.

FY 2017-18

Summary
Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults and among the leading causes of cancer related deaths in the youngests of them. Despite advances in supportive care to treat therapy-related complications, the majority of AML patients will not exceed the two-year survival mark because of disease relapse. This dismal outcome reflects both the presence of high-risk mutations, making many AMLs resistant to conventional chemotherapy, and the sub-optimal treatment orientation of poorly understood subtypes of AML. To improve the treatment and outcome of AML patients, Dr Guy Sauvageau and colleagues initiated in 2009 the Leucegene group, which has become an internationally acknowledged leader in genetic and biological characterization of AML subgroups. Exploiting the most innovative technologies in genome sequencing and biochemistry, this group has already identified a new marker and generated a simple test able to predict the resistance to current AML therapies and to reclassify a quarter of patients otherwise lacking any recognizable markers. Following this success, the project proposed here is intended to identify novel gene modifications and their expression among 452 patients through innovative analysis technics, including machine learning approaches. This will allow a better definition of the rarest AML subgroups, the discovery of new ones, as well as an increase in the chances of identifying new markers. With the goal to accelerate the transfer of new knowledge from the laboratory to the bedside, this project will help ensure the correct classification and treatment of the most misunderstood and deadly forms of AML.
Program
CIHR Fellowship
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
376983
Name
Spinella Jean-François
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Innovative characterization of structural variants and differential splicing from RNA-sequencing data of 452 primary human AML specimens.
Programtype2
Fellowship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Acute Myeloid Leukemia; Biomarkers; Cancer; Differential Splicing; Genomic; Machine Learning; Rna-Sequencing; Structural Variants
Abstract
Acute myeloid leukemia (AML) is the most common form of acute leukemia in adults and among the leading causes of cancer related deaths in the youngests of them. Despite advances in supportive care to treat therapy-related complications, the majority of AML patients will not exceed the two-year survival mark because of disease relapse. This dismal outcome reflects both the presence of high-risk mutations, making many AMLs resistant to conventional chemotherapy, and the sub-optimal treatment orientation of poorly understood subtypes of AML. To improve the treatment and outcome of AML patients, Dr Guy Sauvageau and colleagues initiated in 2009 the Leucegene group, which has become an internationally acknowledged leader in genetic and biological characterization of AML subgroups. Exploiting the most innovative technologies in genome sequencing and biochemistry, this group has already identified a new marker and generated a simple test able to predict the resistance to current AML therapies and to reclassify a quarter of patients otherwise lacking any recognizable markers. Following this success, the project proposed here is intended to identify novel gene modifications and their expression among 452 patients through innovative analysis technics, including machine learning approaches. This will allow a better definition of the rarest AML subgroups, the discovery of new ones, as well as an increase in the chances of identifying new markers. With the goal to accelerate the transfer of new knowledge from the laboratory to the bedside, this project will help ensure the correct classification and treatment of the most misunderstood and deadly forms of AML.
Competitiondate
201711
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Spinella, Jean-François
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~
Université de Montréal - $135,000 Grant (2017-18) | Canada Spends